| HRA005236
(Controlled Access)
|
Only fewer than 5% GBM patients survive over 5 years and referred as long-term survivors (LTS), yet the underlying molecular background of these LTS are insufficiently understood. Herein, we employed comprehensive whole exome sequencing (WES), RNA-seq and methylation array to delineate molecular landscape of the largest LTS cohort to date. Our cohort consisted of 78 primary GBM patients and were divided into LTS (n = 37) and short-term survivors (STS, OS <= 24 months, n = 41), all confirmed being isocitrate dehydrogenase (IDH)-wildtype. These is the raw data of WES, RNAseq, and Bisulfite sequencing of the project. |
